Investment analysts at Aegis assumed coverage on shares of Cogentix Medical (NASDAQ:CGNT) in a report released on Friday, The Fly reports. The firm set a “buy” rating on the medical device company’s stock.

Other equities analysts also recently issued research reports about the company. Zacks Investment Research upgraded Cogentix Medical from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a research note on Friday, August 4th. TheStreet upgraded Cogentix Medical from a “d+” rating to a “c” rating in a research note on Thursday, November 9th. Roth Capital started coverage on Cogentix Medical in a research note on Wednesday, November 8th. They set a “buy” rating and a $4.00 price objective on the stock. Finally, JMP Securities started coverage on Cogentix Medical in a research note on Friday, October 6th. They set an “outperform” rating and a $5.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. Cogentix Medical presently has an average rating of “Buy” and an average price target of $3.83.

Shares of Cogentix Medical (NASDAQ:CGNT) opened at $2.86 on Friday. Cogentix Medical has a 1 year low of $1.55 and a 1 year high of $3.26.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP bought a new stake in shares of Cogentix Medical during the third quarter valued at about $152,000. Northern Trust Corp raised its stake in shares of Cogentix Medical by 0.4% during the second quarter. Northern Trust Corp now owns 73,926 shares of the medical device company’s stock valued at $129,000 after purchasing an additional 326 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Cogentix Medical by 2.3% during the first quarter. Renaissance Technologies LLC now owns 562,996 shares of the medical device company’s stock worth $1,013,000 after acquiring an additional 12,459 shares during the period. Finally, Broadfin Capital LLC grew its holdings in Cogentix Medical by 45.2% during the second quarter. Broadfin Capital LLC now owns 1,094,544 shares of the medical device company’s stock worth $1,905,000 after acquiring an additional 340,771 shares during the period. Institutional investors and hedge funds own 13.33% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/01/aegis-initiates-coverage-on-cogentix-medical-cgnt.html.

About Cogentix Medical

Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).

The Fly

Receive News & Ratings for Cogentix Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.